Clinical Trials
11 trialsNCT01210482 2024-09-25
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Pfizer
Completed
NCT01517243 2023-09-21
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00112840 2022-02-01
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00378703 2018-11-14
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT00782275 2018-01-24
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00631371 2016-04-27
INTORACT
Pfizer
Phase 3 Completed
NCT01367457 2016-04-27
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
Pfizer
Completed
NCT00474786 2013-11-21
INTORSECT
Pfizer
Phase 3 Completed
NCT00065468 2012-10-25
ARCC
Pfizer
Phase 3 Completed